Skip to main content

Olema Pharmaceuticals, Inc.

OLMA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001750284

In the last 90 days, Olema Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 1 sale; 185 institutions reported holding it in 13F filings for Q2 2026, worth $1.28B in total; Duquesne Family Office is the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Olema Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
1 filing
1 insider, $291.2K in total
Insiders trading
1
Net value
−$291.2K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Olema Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Olema Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
O'Byrne JasonCHIEF FINANCIAL OFFICER–Sep 2, 20261
Harmon CyrusDirector702,770Jul 27, 20265
Biotechnology Value Fund L PDirector, Other: See Explanation of Responses347,970Jun 23, 20261
BVF Partners L PDirector, Other: See Explanation of Responses347,970Jun 23, 20261
BVF IncDirector, Other: See Explanation of Responses347,970Jun 23, 20261
Biotechnology Value Fund II LPDirector, Other: See Explanation of Responses347,970Jun 23, 20261
Lampert Mark NDirector, Other: See Explanation of Responses347,970Jun 23, 20261
Biotechnology Value Trading Fund OS LPDirector, Other: See Explanation of Responses347,970Jun 23, 20261
BVF Partners OS Ltd.Director, Other: See Explanation of Responses347,970Jun 23, 20261
BVF I GP LLCDirector, Other: See Explanation of Responses347,970Jun 23, 20261
BVF II GP LLCDirector, Other: See Explanation of Responses347,970Jun 23, 20261
BVF GP Holdings LLCDirector, Other: See Explanation of Responses347,970Jun 23, 20261
Rappaport AndrewDirector0Jun 23, 20262
Butitta Cynthia MDirector–Jun 23, 20261
Clark Ian TDirector0Jun 23, 20262
Garland J. ScottDirector–Jun 23, 20261
Horning SandraDirector–Jun 23, 20261
Graham G. WalmsleyDirector700,761IndirectJun 23, 20261
Larson YiDirector–Jun 23, 20261
Hrustanovic GorjanDirector–Jun 23, 20261
Raman PrakashDirector–Jun 23, 20262
Mitchell ShawnteCHIEF LEGAL OFFICER0Mar 5, 20262
Austin Sasha LuVP of Finance and Controller16,188Feb 17, 20261
Myles David C.CH. DISCOV. & NON-CLIN DEV OFF542,761Feb 4, 20263
Bohen SeanPRESIDENT AND CEO237,650Feb 4, 20262
Zojwalla NaseemCHIEF MEDICAL OFFICER4,488Feb 4, 20262
Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF.139,727Jan 15, 20263
Bain Capital Life Sciences Investors, LLC10% Owner4,300,000IndirectJan 13, 20250
Bain Capital Life Sciences IV General Partner, LLC10% Owner4,300,000IndirectJan 13, 20250
Bain Capital Life Sciences Fund IV, L.P.10% Owner4,300,000IndirectJan 13, 20250
Bain Capital Life Sciences Opportunities IV, L.P.10% Owner4,300,000IndirectJan 13, 20250
Bain Capital Life Sciences Opportunities IV GP, LLC10% Owner4,300,000IndirectJan 13, 20250
Paradigm BioCapital International Fund Ltd.10% Owner783,118IndirectAug 5, 20240
Paradigm Biocapital Advisors LP10% Owner783,118IndirectAug 5, 20240
Paradigm BioCapital Advisors GP LLC10% Owner783,118IndirectAug 5, 20240
Asefaw Senai10% Owner783,118IndirectAug 5, 20240
Moriarty John BEVP, Ch. Legal Officer & Sec.–Feb 2, 20230
Horn KinneyChief Business Officer2,458Feb 2, 20230
Kushner Peter J.CHIEF SCIENTIFIC OFFICER–Feb 3, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 27, 2026 (view filing)7:30 PM ETJul 23-244 daysHarmon CyrusDirectorSSale−25.0K$11.65−$291.2K−3.4%702.8K after2 lots
Mar 5, 2026 (view filing)Mar 3-42 daysMitchell ShawnteCHIEF LEGAL OFFICERSSale−39.8K$23.78−$945.7K−99.4%233 after2 lots
Mar 5, 2026 (view filing)Mar 41 dayMitchell ShawnteCHIEF LEGAL OFFICERSSaleComon Stock−233$24.69−$5.75K−100.0%0 after
Jan 21, 2026 (view filing)Jan 201 dayHarmon CyrusDirectorSSale−10.0K$26.88−$268.8K−1.4%727.8K after
Jan 16, 2026 (view filing)Jan 142 daysHarmon CyrusDirectorSSale−3.49K$29.12−$101.6K−0.5%737.8K after
Jan 15, 2026 (view filing)Jan 13-152 daysKovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF.SSale−103.8K$28.70−$2.98M−42.6%139.7K after2 lots
Jan 14, 2026 (view filing)Jan 122 daysMyles David C.CH. DISCOV. & NON-CLIN DEV OFFSSale−10.0K$28.34−$283.4K−6.5%144.8K after
Jan 14, 2026 (view filing)Jan 13-141 dayMyles David C.CH. DISCOV. & NON-CLIN DEV OFFSSale−100.0K$28.24−$2.82M−15.6%542.8K after4 lots
Dec 29, 2025 (view filing)Dec 227 daysHarmon CyrusDirectorSSale−2.88K$28.53−$82.2K−0.4%741.3K after
Dec 23, 2025 (view filing)Dec 19-234 daysZojwalla NaseemChief Medical OfficerSSale−269.5K$27.94−$7.53M−98.4%4.49K after4 lots
Dec 23, 2025 (view filing)Dec 194 daysMyles David C.CH. DISCOV. & NON-CLIN DEV OFFSSale−51.0K$30.46−$1.55M−8.5%551.9K after3 lots
Dec 23, 2025 (view filing)Dec 194 daysClark Ian TDirectorSSale−264.8K$29.73−$7.87M−100.0%0 after3 lots
Sep 18, 2025 (view filing)Sep 16-182 daysHarmon CyrusDirectorSSale−20.0K$8.19−$163.7K−2.6%744.1K after2 lots
Sep 18, 2025 (view filing)Sep 16-182 daysHarmon CyrusDirectorSSale−5.00K$8.23−$41.1K−4.1%117.0K after2 lots
Jan 13, 2025 (view filing)4:34 PM ETJan 85 daysBain Capital Life Sciences Investors, LLC and 4 others10% OwnerPPurchase+300.0K$5.76+$1.73M+4.0%7.80M after
Dec 18, 2024 (view filing)Dec 135 daysGraham G. WalmsleyDirectorSSale−700.8K$6.75−$4.73M−100.0%0 afterFrom original
Dec 18, 2024 (view filing)Dec 135 daysGraham G. WalmsleyDirectorPPurchase+700.8K$6.75+$4.73MNew position700.8K afterFrom original
Dec 11, 2024 (view filing)Dec 10-111 dayHarmon CyrusDirectorSSale−16.4K$9.03−$148.0K−2.1%764.1K after3 lots
Dec 11, 2024 (view filing)Dec 10-111 dayMyles David C.CH. DISCOV. & NON-CLIN DEV OFFSSale−26.1K$9.01−$234.9K−4.2%598.3K after3 lots
Dec 11, 2024 (view filing)Dec 10-111 dayZojwalla NaseemCHIEF MEDICAL OFFICERSSale−27.8K$9.01−$250.5K−19.4%115.5K after3 lots
Dec 11, 2024 (view filing)Dec 10-111 dayKovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF.SSale−35.2K$9.01−$316.7K−6.1%543.5K after3 lots
Dec 11, 2024 (view filing)Dec 10-111 dayBohen SeanPRESIDENT AND CEOSSale−109.5K$9.01−$986.4K−31.2%241.7K after3 lots
Nov 26, 2024 (view filing)Jun 4175 daysGraham G. WalmsleyDirectorSSale−1.18M$14.85−$17.4M−62.4%708.1K afterAmended2 lots
Aug 5, 2024 (view filing)4:30 PM ETAug 14 daysParadigm BioCapital International Fund Ltd. and 3 others10% OwnerSSaleCommon Stock, par value $0.0001 per share−2.40M$14.92−$35.8M−75.4%783.1K after2 lots
Jul 31, 2024 (view filing)Jul 29-302 daysHarmon CyrusDirectorSSale−5.00K$15.57−$77.9K−0.7%751.3K after2 lots10b5-1
Jul 12, 2024 (view filing)Jul 111 dayHarmon CyrusDirectorSSale−5.00K$12.26−$61.3K−0.7%756.3K after10b5-1
Jul 2, 2024 (view filing)Jun 284 daysHarmon CyrusDirectorSSale−20.0K$10.77−$215.4K−2.6%761.3K after10b5-1
Jun 4, 2024 (view filing)May 31-Jun 44 daysHarmon CyrusDirectorSSale−25.0K$10.30−$257.4K−3.1%781.3K after3 lots10b5-1
May 7, 2024 (view filing)May 61 dayHarmon CyrusDirectorSSale−5.00K$10.92−$54.6K−0.6%806.3K after10b5-1
May 2, 2024 (view filing)Apr 302 daysHarmon CyrusDirectorSSale−15.0K$9.51−$142.7K−1.8%811.3K after10b5-1
Mar 29, 2024 (view filing)Mar 281 dayHarmon CyrusDirectorSSale−20.0K$10.97−$219.4K−2.4%826.3K after10b5-1
Mar 4, 2024 (view filing)Feb 294 daysHarmon CyrusDirectorSSale−25.0K$12.41−$310.3K−2.9%846.3K after2 lots10b5-1
Feb 2, 2024 (view filing)Jan 31-Feb 12 daysHarmon CyrusDirectorSSale−30.0K$12.79−$383.6K−3.3%871.3K after2 lots10b5-1
Jan 2, 2024 (view filing)Dec 29, 20234 daysHarmon CyrusDirectorSSale−25.0K$13.38−$334.5K−2.7%901.3K after2 lots
Dec 18, 2023 (view filing)Sep 12-Dec 597 daysLateGraham G. WalmsleyDirectorPPurchase+640.0K$10.74+$6.87M+55.2%1.80M after4 lots
Dec 8, 2023 (view filing)4:19 PM ETDec 62 daysParadigm BioCapital International Fund Ltd. and 3 others10% OwnerPPurchaseCommon Stock, par value $0.0001 per share+100.0K$11.60+$1.16M+1.5%6.59M after
Dec 1, 2023 (view filing)Nov 301 dayHarmon CyrusDirectorSSale−25.0K$12.57−$314.3K−2.6%926.3K after10b5-1
Nov 22, 2023 (view filing)Nov 21-221 dayZojwalla NaseemCHIEF MEDICAL OFFICERSSale−14.6K$14.38−$209.3K−32.2%30.7K after3 lots
Nov 22, 2023 (view filing)Nov 21-221 dayMyles David C.CH. DISCOV. & NON-CLIN DEV OFFSSale−13.6K$14.40−$196.2K−2.3%574.1K after3 lots
Nov 22, 2023 (view filing)Nov 21-221 dayHarmon CyrusDirectorSSale−8.18K$14.39−$117.7K−0.9%951.3K after2 lots
Nov 22, 2023 (view filing)Nov 21-221 dayBohen SeanPRESIDENT AND CEOSSale−57.2K$14.40−$824.1K−28.3%144.9K after3 lots
Nov 22, 2023 (view filing)Nov 21-221 dayKovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF.SSale−18.7K$14.39−$269.7K−4.2%425.0K after3 lots
Nov 13, 2023 (view filing)Nov 85 daysMyles David C.CH. DISCOV. & NON-CLIN DEV OFFSSale−200$17.61−$3.52K0.0%561.3K after10b5-1
Nov 3, 2023 (view filing)Nov 1-32 daysMyles David C.CH. DISCOV. & NON-CLIN DEV OFFSSale−10.5K$15.26−$160.8K−1.8%561.5K after3 lots10b5-1
Nov 2, 2023 (view filing)Oct 31-Nov 22 daysHarmon CyrusDirectorSSale−30.0K$12.65−$379.4K−3.1%943.7K after2 lots10b5-1
Oct 3, 2023 (view filing)Sep 294 daysHarmon CyrusDirectorSSale−25.0K$12.41−$310.3K−2.5%973.7K after10b5-1
Sep 21, 2023 (view filing)Sep 192 daysMyles David C.CH. DISCOV. & NON-CLIN DEV OFFSSale−20.0K$12.67−$253.4K−3.4%572.0K after10b5-1
Sep 14, 2023 (view filing)4:25 PM ETSep 122 daysBiotechnology Value Fund L P and 9 othersDirector, Other: See Explanation of ResponsesPPurchaseCommon stock, $0.0001 par value+1.51M$9.84+$14.8MNew position524.2K after3 lots
Sep 5, 2023 (view filing)Aug 31-Sep 55 daysHarmon CyrusDirectorSSale−25.0K$10.26−$256.6K−2.4%998.7K after2 lots10b5-1
Sep 5, 2023 (view filing)Aug 1620 daysHarmon CyrusDirectorSSale−15.0K$10.14−$152.1K−1.4%1.02M afterAmended10b5-1